MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z
  • Factitious Disorder Imposed on Another mimicking a Dopamine Dysregulation Syndrome

    DRC. Carneiro, MS. Sousa, ASM. Morgadinho, CJ. Januário (Coimbra, Portugal)

  • Factors Affecting Mortality in Late Stage Parkinson’s Disease

    S. Dempsey, L. Mcdonald, I. Sayers, WK. Gray, A. Hand, R. Walker (Newcastle Upon Tyne, United Kingdom)

  • Factors associated with dyskinesia in Parkinson’s disease in Mainland China

    X. Zhou, LF. Fang, XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

  • Factors Influencing Decision-Making About End of Life Care in Patients With Parkinson’s Disease and Their Family Members

    R. Bužgová, R. Kozáková, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

  • Factors that interfere in the functionality according to Functional Independence Measure in people with Parkinson’s Disease.

    E. Libardi, M. Piemonte, E. Guelfi, E. Okamoto (São Paulo, Brazil)

  • Factors underlying reduced aerobic capacity in Huntington disease

    A. Rao, S. Norris, J. Montes, P. Wasserman, K. Marder (New York, NY, USA)

  • Fall History and Gait Variability can Predict Falls in Individuals With Parkinson’s Disease

    L. Ma, P. Chan (Beijing, China)

  • Familial Creutzfeldt-Jakob disease with D178N and Met129Val

    N. Omer, E. Kahana, S. Simchoni, A. Bar-Shira, T. Naiman, A. Orr-Urtreger, B. Aminov, D. Klepikov, N. Giladi, N. Bregman (Tel Aviv, Israel)

  • Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

    C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

  • Fatigue in Parkinson’s Disease

    D. Silva, TR. Alcântara-Silva, AL. Alcântara-Silva, S. Suzuki-Godoy (Goiânia, Brazil)

  • Fatigue in Parkinson’s disease and its relation with disease duration and treatment

    D. Nassif, J. Pereira (Rio de Janeiro, Brazil)

  • FDG PET: a good predictive tool for CNS inflammation

    M. Nader, F. Fluchere, T. Witjas, A. Eusebio, JP. Azulay (Marseille, France)

  • Feasibility and acceptability of a therapist-delivered physical activity coaching intervention for people with premanifest and early stage Huntington’s Disease and Parkinson’s Disease

    K. Long Ms, M. Caciula Phd, C. Friel Edd, L. Quinn Edd (New York City, NY, USA)

  • Features of neural activity of globus pallidus in a patient with cervical dystonia and putaminal stroke: case study

    A. Gamaleya, A. Tomskiy, S. Usova, V. Popov, AG. Shaikh, A. Sedov (Moscow, Russian Federation)

  • Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.

    H. Bouchaoui, L. Mahoney-Sanchez, A. Jonneaux, F. Gouel, M. Dutheil, JC. Devedjian, G. Garçon, D. Devos (Lille, France)

  • Fine-mapping of SNCA variants in REM sleep behavior disorder identifies distinct associations

    L. Krohn, R. Wu, J. Ruskey, S. Laurent, L. Philstrom, I. Arnulf, M. Hu, Y. Dauvilliers, B. Hogl, A. Stefani, E. Holzknecht, C. Monaca, A. Beatriz, G. Plazzi, E. Antelmi, L. Ferini-Strambi, A. Heidbreder, V. Cochen, B. Mollenhauer, K. Sonka, M. Figorilli, F. Dijkstra, M. Viaene, W. Oertel, J. Gagnon, M. Nalls, C. Blauwendraat, A. Singleton, A. Desautels, J. Montplaisir, O. Ross, B. Boeve, N. Dupre, E. Fon, R. Postuma, G. Rouleau, Z. Gan-Or (Montreal, QC, Canada)

  • Firing pattern of single neurons in the subthalamic nucleus of Tourette Syndrome patients identifies optimal deep brain stimulation target site

    M. Vissani, R. Cordella, S. Micera, L. Romito, A. Mazzoni (Pontedera, Italy)

  • First Experience with MR-guided Focused Ultrasound in the Treatment of X-linked Dystonia-Parkinsonism (XDP)

    WC. Chang, T. Taira, RDG. Jamora, PY. Chiu, W. Lin (Changhwa, Taiwan)

  • First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit

    JB. Paredes, J. Poles, V. Hristova, S. Madrona, S. Argos, P. Torre, JL. Moreno, I. Moreno, JC. Castrillo, A. Canovas (Madrid, Spain)

  • First-In-Human Study of LY3154207, a Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)

    K. Biglan, K. Svensson, W. Kielbasa (Indianapolis, IN, USA)

  • Fixation suppression the easy way – when nothing else matters

    F. Gandor, M. Tesch, H. Neuhauser, D. Gruber, HJ. Heinze, G. Ebersbach, T. Lempert (Beelitz-Heilstaetten, Germany)

  • Focus on the Locus: Ultra-high field MRI evaluation of locus coeruleus structure and function in Parkinson’s Disease

    C. Madelung, D. Meder, A. Løkkegaard, H. Siebner (Hvidovre, Denmark)

  • Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism

    A. Jain, S. Jain (Sagar, India)

  • Four square step test in patients with early de novo Parkinson’s disease

    JH. Kim, YM. Park, IS. Kim, SB. Koh (Seoul, Republic of Korea)

  • Four-Week Trunk-Specific Exercise Program decreases Forward Trunk Flexion in Parkinson’s disease: a single- blinded, randomized controlled trial

    M. Gandolfi, M. Tinazzi, F. Magrinelli, G. Buselli, E. Dimitrova, N. Polo, P. Manganotti, A. Fasano, N. Smania, C. Geroin (Verona, Italy)

  • Fractional anisotropy patterns in non-demented Parkinson’s disease patients using hierarchical cluster analysis

    H. Erostarbe, A. Inguanzo, R. Sala, A. Abos, A. Campabadal, C. Uribe, H. Baggio, Y. Compta, M. Marti, F. Valldeoriola, C. Junque, B. Segura (Barcelona, Spain)

  • Fragile X Gray Zone Alleles in Men are associated with Parkinsonism

    D. Hall, S. Nag, E. Berry-Kravis, A. Ali, B. Ouyang, Y. Liu, A. Buchman, D. Bennett (Chicago, IL, USA)

  • Fragile X syndrome presenting with levodopa unresponsive parkinsonism

    J. Mayer, J. Panicker, S. Alusi (Liverpool, United Kingdom)

  • Frailty in Parkinson’s disease: A systematic review

    N. Smith, L. Brennan, D. Gaunt, Y. Ben-Shlomo, E. Henderson (Bath, United Kingdom)

  • Frailty status predicts falls in early Parkinson’s disease

    S. Holland, R. Morris, B. Galna, L. Rochester, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

  • Freezer or non-freezer: what is in between?

    M. Mancini, K. Smulders, S. Stuart, R. Morris, F. Horak, J. Nutt (Portland, OR, USA)

  • Freezing of gait as a reflection of disturbed general time processing in Parkinson’s disease? A new look on a complex phenomenon

    J. Wagner, A. Gulberti, J. Verrel, S. Tunc, T. Bäumer, W. Hamel, AK. Engel, C. Gerloff, CKE. Moll, A. Münchau, M. Pötter-Nerger (Hamburg, Germany)

  • Freezing of Gait in Parkinson’s Disease: Risk Factors and Associated Nonmotor Symptoms

    D. Lichter, L. Hershey (Buffalo, NY, USA)

  • Freezing of gait in Parkinson’s disease: a review of current neuroimaging evidence for the development of effective therapies

    A. Potvin-Desrochers, C. Paquette (Montreal, QC, Canada)

  • Frequency and pattern of movement disorders in a Neurologic clinic in North Central Nigeria: a 3- year review

    E. Iwuozo, R. Obiako (Makurdi, Nigeria)

  • Frequency of Cardiovascular Abnormalities in Mexican Patients with Early Parkinson´s Disease

    JA. Juárez, M. Violante, A. Arriaga, A. González, A. Salas, L. Vidal, R. Vicioso, C. Roa, I. López, M. Soto (Mexico, Mexico)

  • Frequency of impulse control disorder in Parkinson’s disease: insights from the Luxembourg cohort

    S. Binck, C. Pauly, P. Kolber, L. Pavelka, L. Stute, D. Reiter, M. Vaillant, M. Gantenbein, E. Glaab, J. Ferrand, L. Geffers, G. Hipp, R. Krueger, NJ. Diederich (Strassen, Luxembourg)

  • Frequency of neuropsychiatric symptoms in non-demented early and late-onset Parkinson’s disease patients

    A. Seubert-Ravelo, MG. Yáñez-Téllez, G. Neri-Nani, X. Ortiz-Jiménez, C. Guerra-Galicia (Estado de México, Mexico)

  • Frequency of PD Non-Motor symptoms in healthy factory workers

    C. Guerra-Galicia, C. Tenorio (San Luis Potosí, Mexico)

  • Frequency-dependent abnormalities of intrinsic brain activity in Parkinson´s disease

    L. Krajcovicova, R. Marecek, I. Rektorova (Brno, Czech Republic)

  • Frequency, course and predictors of fatigue in Parkinson’s disease patients and population-based controls

    E. Warrlich, EJ. Vollstedt, R. Modreanu, B. Hauptmann, V. Tadic, S. Tunc, C. Kritzinger, J. Prasuhn, A. Balck, M. Borsche, H. Hanssen, N. Brüggemann, C. Klein, M. Kasten (Luebeck, Germany)

  • Functional and dysfunctional impulsivities changes after deep brain stimulation of the subthalamic nucleus

    R. Kardous, B. Giordana, L. Stefanini, H. Joly, A. Mulliez, C. Giordana, B. Bailet, M. Borg, J. Yelnik, JJ. Lemaire, M. Benoit, D. Fontaine (Nice, France)

  • Functional Biomarkers of Parkinson’s Disease: Changes in Brain-Wide Network Connectivity in Default Mode and Fronto-Parietal Control Networks

    P. Macdonald, N. Hiebert, L. Naci, A. Owen (Dublin, Ireland)

  • Functional Bowel Symptoms in Parkinson´s Disease

    K. Murtomäki, T. Mertsalmi, E. Jaakkola, E. Mäkinen, J. Joutsa, R. Levo, E. Pekkonen, V. Kaasinen, F. Scheperjans (Hus, Finland)

  • Functional brain connectome in drug-naïve Parkinson’s disease patients

    R. de Micco, F. Agosta, S. Basaia, M. Siciliano, C. Cividini, G. Tedeschi, A. Tessitore, M. Filippi (Naples, Italy)

  • Functional Capacity in patients with Parkinson’s Disease are related to advanced glycation end-products

    JEN. Almeida, NAT. Luna, ROD. Iborra, ANG. Alonso, ADR. -Lima (São Paulo, Brazil)

  • Functional connectivity and microstructural alterations in regions of synaptic density loss in DLB and PDD

    T. Yousaf, G. Dervenoulas, G. Pagano, C. Loane, H. Wilson, A. Chandra, O. Cousins, R. Gunn, E. Rabiner, F. Niccolini, M. Esposito, L. Ricciardi, D. Aarsland, M. Politis (London, United Kingdom)

  • Functional connectivity within the cerebellum and brainstem in essential tremor patients– a tailored resting state fMRI approach

    S. Sharifi, ES. Scheijbeler, WVP. Potters, AFR. Rootselaar (Amsterdam, Netherlands)

  • Functional connectome in Parkinson’s disease mild cognitive impairment

    M. Delgado-Alvarado, V. Ferrer-Gallardo, I. Navalpotro-Gómez, S. Moia, M. Carreiras, C. Caballero-Gaudes, MC. Rodríguez-Oroz (Torrelavega, Spain)

  • Functional exam findings in Lewy Body Disease

    J. Nguyen, K. Papesh (Las Vegas, NV, USA)

  • Functional Limits of Stability and Standing Balance in people with and without Freezing of Gait

    N. Hasegawa, K. Maas, V. Shah, P. Carlson-Kuhta, J. Nutt, F. Horak, T. Asaka, M. Mancini (Portland, OR, USA)

  • Functional magnetic-resonant imaging in child cerebral palsy with epilepsy

    D. Aminova, K. Aminov (Tashkent, Uzbekistan)

  • Functional mobility tests and their relationship with disease stage in patients with Parkinson’s Disease

    B. üğüt, T. Kahraman, A. Kalkan, A. Genç, B. çolakoğlu (Izmir, Turkey)

  • FUNCTIONAL MOTOR SYMPTOMS IN PARKINSON’S DISEASE, AND FUNCTIONAL PARKINSONISM: A SYSTEMATIC REVIEW

    M. Ambar Akkaoui, P. Geoffroy, E. Roze, B. Degos, B. Garcin (Bobigny, France)

  • Functional MRI activation during the Symbol Digit Modalities Test in Parkinson’s disease

    G. Grolez, R. Viard, R. Lopes, JP. Pruvo, K. Dujardin, L. Defebvre, C. Moreau (Lille, France)

  • Functional Proteomic Analysis of Leukocytes from Parkinson’s Disease Patients: A Clinical Perspective on Biomarkers Identification

    N. Woldmar, B. Fadel, G. Poralla, L. Giacomin, J. Evaristo, F. Nogueira, A. Rosso, L. Pizzatti (Rio de Janeiro, Brazil)

  • Functional stiff person like disorders: clinical features and red flags

    B. Balint, A. Jha, M. Edwards, HM. Meinck, K. Bhatia (London, United Kingdom)

Jump to:  View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley